Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | PHASE2 | ACTIVE NOT_RECRUITING | 350 | — | — | Jan 4, 2019 | Jun 1, 2026 | Apr 3, 2026 | 66 | United States, Belgium +5 |
The standard assessments used to assign a score to any affected organ system as per the NCI CTCAE 4.03 will be conduced at each protocol-specified timepoint.
To determine the 1-year survival rate of patients treated on the 9-ING-41 schedule chosen from the run-in stage of the study compared to the control arm
| Arm | Type | Description |
|---|---|---|
| 9-ING-41 | EXPERIMENTAL | Drug: 9-ING-41 |
| 9-ING-41 plus Gemcitabine | EXPERIMENTAL | Drugs: Gemcitabine - 21 day cycle. 9-ING-41 |
| 9-ING-41 plus Doxorubicin | EXPERIMENTAL | Drugs: Doxorubicin. 9-ING-41 |
| 9-ING-41 plus Lomustine | EXPERIMENTAL | Drugs: Lomustine. 9-ING-41. |
| 9-ING-41 plus Carboplatin | EXPERIMENTAL | Drugs: Carboplatin. 9-ING-41. |
| 9-ING-41 plus nab paclitaxel Gemcitabine | EXPERIMENTAL | Drugs: Nab-paclitaxel. Gemcitabine - 28 day cycle. 9-ING-41. |
| 9-ING-41 plus Paclitaxel/Carboplatin | EXPERIMENTAL | Drugs: Paclitaxel. Carboplatin. 9-ING-41. |
| 9-ING-41 plus Irinotecan | EXPERIMENTAL | Drugs: Irinotecan. 9-ING-41. |
| Name | Type | Description |
|---|---|---|
| 9-ING-41 | DRUG | Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes. |
| Gemcitabine - 21 day cycle | DRUG | Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle |
| Doxorubicin. | DRUG | Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2. |
| Lomustine | DRUG | Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks. |
| Carboplatin. | DRUG | Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle. |
| Nab paclitaxel. | DRUG | Nab-paclitaxel 125 mg/m2 intravenously on Days 1, 8 and 15 of a 28-day cycle |
| Paclitaxel. | DRUG | Paclitaxel 175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle. |
| Gemcitabine - 28 day cycle | DRUG | Gemcitabine 1000 mg/m2 intravenously over 30-minutes on Days 1, 8 and 15 of a 28-day cycle |
| Irinotecan | DRUG | Irinotecan 350 mg/m2 intravenously over 90-minutes on Day 1 of a 21-day cycle |
Inclusion Criteria: * Patient - 1. Is able to understand and voluntarily sign a written informed consent and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures. 2. Is aged ≥ 18 years 3. Has path...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |